天龙咳喘灵治疗慢性阻塞性肺疾病的物质基础及作用机制的网络药理学研究  

Study on the Mechanism of Action of Tianlong Kechuanling in Treating Chronic Obstructive Pulmonary Disease Based on Network Pharmacology

作　　者：王鹏[1] 刘小虹[1] 朱汉平[2] 潘俊辉[2] 张晓云 WANG Peng;LIU Xiaohong;ZHU Hanping;PAN Junhui;ZHANG Xiaoyun(Guangzhou University of Chinese Medicine, Guangzhou 510405 Guangdong, China;The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120 Guangdong, China;Guangzhou Medical University, Guangzhou 511436 Guangdong, China)

机构地区：[1]广州中医药大学,广东广州510405 [2]广州医科大学附属第一医院,广东广州510120 [3]广州医科大学,广东广州511436

出　　处：《中药新药与临床药理》2018年第3期365-371,共7页Traditional Chinese Drug Research and Clinical Pharmacology

基　　金：广东省中医药科学院联合科研专项(2013A032500015)

摘　　要：以网络药理学的方法探讨天龙咳喘灵治疗慢性阻塞性肺疾病(COPD)的药效物质基础和分子作用机制。方法利用中药系统药理学数据库与分析平台(TCMSP)获取天龙咳喘灵的化学成分,并根据Lipinski规则(LR)、口服生物利用度(Oral bioavailability,OB)以及药物相似性(Drug-likeness,DL)对潜在的生物活性成分进行分析鉴定;利用BATMAN-TCM对获得的活性成分进行生物信息学分析。结果从天龙咳喘灵复方中获得1258种化学成分,并根据LR、OB及DL特性筛选出80种潜在有效成分。共得到145条KEGG通路,其中显著富集的KEGG通路有29条。进一步筛选后获得了36条生物过程(BP,biological process)、10条细胞组分(CC,cellular component)、7条分子功能(MF,molecular function)。根据OMIM数据库分析预测出天龙咳喘灵潜在的治疗疾病188个;根据TTD数据库分析预测出天龙咳喘灵潜在治疗作用的疾病30个。结论天龙咳喘灵治疗COPD的作用机制可能是通过影响ADRB2、CACNA1C、ARRB2、ADRA1A、ADRA1B、ADRA1C、HTR2A、HTR2B、HTR2C和CHRM2等靶点,调控MAPK信号通路、趋化因子信号通路、TRP通道的炎症介质调节、血管平滑肌收缩通路及PI3K-Akt信号通路。Objective To explore the mechanism of Tianlong Kechuanling in the treatment of chronic obstructive pulmonary disease by network pharmacology. Methods Identification of potentially bioactive components in Tianlong Kechuanling was carried out by digging relative information in TCMSP database. According to Lipinski’s rules（LR）, phytochemical information of compounds with oral bioavailability（OB）and drug-likeness（DL）properties were explored using the TCMSP database. Bioinformatics analysis using BATMAN-TCM system was conducted. Results 1258 phytochemicals from Tianlong Kechuanling was obtained. Among them, 80 compounds met all criteria were selected based on LR, OB and DL. After bioinformatics analysis of these compounds by BATMAN-TCM, a total of 145 KEGG pathways were obtained, of which 29 were significantly enriched KEGG pathways. After further screening,36 biological processes,10 cellular components,and 7 molecular functions were obtained. Based on the OMIM database, 188 potential treatments for Tianlong Kechuanling were predicted,including asthma and pulmonary hypertension. Based on TTD database, 30 potential treatments for Tianlong Kechuanling were predicted. Conclusion The effective mechanism for active ingredients of Tianlong Kechuanling treating COPD may be through regulating MAPK signaling pathway, chemokine signaling pathway,inflammatory mediators of TRP channels, vascular smooth muscle contraction, MAPK signaling pathway, PI3 K-Akt signaling pathway. ADRB2, CACNA1 C, ARRB2, ADRA1 A, ADRA1 B, ADRA1 C, HTR2 A, HTR2 B, HTR2 C and CHRM2 are potential therapeutic targets for the treatment of lung diseases by Tianlong Kechuanling.

关 键 词：天龙咳喘灵 慢性阻塞性肺疾病 网络药理学 

分 类 号：R285.5[医药卫生—中药学] R563[医药卫生—中医学]